Publications by authors named "Y Tanigawara"
Multiple myeloma (MM) treatment guidelines recommend waiting for formal progression criteria (FPC) to be met before proceeding to the next line of therapy. As predicting progression may allow early switching to next-line therapy while the disease burden is relatively low, we evaluated the predictive accuracy of a mathematical model to anticipate relapse 180 days before the FPC is met. A subset of 470/1143 patients from the IA16 dataset who were initially treated with VRd (Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone) in the CoMMpass study (NCT01454297) were randomly split 2:1 into training and testing sets.
View Article and Find Full Text PDFBackground: In older patients, esophageal squamous cell carcinoma (ESCC) is difficult to treat using standard therapies, including surgery and cisplatin-based chemoradiotherapy. Paclitaxel (PTX) has radiosensitizing activity. We conducted a phase I trial of PTX combined with radiotherapy to establish a standard therapy for locally advanced ESCC in older patients.
View Article and Find Full Text PDFBackground: Neutropenia is a major dose-limiting toxicity of cancer chemotherapy. Semimechanistic mathematical models have been applied to describe the time course of neutrophil counts. The objectives of this study were to develop a mathematical model describing changes in neutrophil counts during eribulin treatment, to apply the empirical Bayes method to predict the probability of developing neutropenia ≥ grade 3 during eribulin treatment in each patient, and to propose the implementation of this mathematical tool in clinical practice for individual safety management.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess how the effectiveness of erlotinib treatment relates to the levels of both total and unbound erlotinib in patients with non-small cell lung cancer (NSCLC) who have specific EGFR mutations.
- A total of 70 patients were enrolled, with 61 possessing EGFR-activating mutations, and findings showed that exposure levels did not correlate with progression-free survival (PFS), which had a median of 10.9 months.
- The analysis indicated that skin toxicity was linked to higher total drug concentrations, but despite variability in patient responses, the standard erlotinib dose of 150 mg/day remains effective for treating NSCLC with the identified mutations.
Background: The aim of this study was to evaluate clinical validity of the S-1 dosage formula based on body surface area (BSA) and creatinine clearance (CLcr) to achieve the target area under the concentration-time curve of 5-FU, which we had developed and refined in each prospective pharmacokinetic study.
Methods: The recommended dose determined by the refined formula was assessed using data of the SPIRITS (S-1 vs. S-1 plus cisplatin [SP]) and the G-SOX (SP vs.